BEAM - Beam Therapeutics Inc Stock Price, Fair Value and News

21.26USD-1.28 (-5.68%)Market Closed

Market Summary

USD21.26-1.28

Market Closed

-5.68%

BEAM Alerts

5 major insider sales recently.

Losses in recent quarter

BEAM Stock Price

View Fullscreen

BEAM RSI Chart

BEAM Valuation

Market Cap

1.9B

Price/Earnings (Trailing)

-13.77

Price/Sales (Trailing)

4.91

EV/EBITDA

-31.2

Price/Free Cashflow

-10.96

BEAM Price/Sales (Trailing)

BEAM Profitability

EBT Margin

-18.78%

Return on Equity

-14.75%

Return on Assets

-9.91%

Free Cashflow Yield

-9.12%

BEAM Fundamentals

BEAM Revenue

Revenue (TTM)

377.7M

Rev. Growth (Yr)

1.5K%

Rev. Growth (Qtr)

1.7K%

BEAM Earnings

Earnings (TTM)

-134.7M

Earnings Growth (Yr)

-2.29%

Earnings Growth (Qtr)

-169.1%

Breaking Down BEAM Revenue

52 Week Range

21.0237.47

(Low)(High)

Last 7 days

-0.8%

Last 30 days

-23.2%

Last 90 days

-22.4%

Trailing 12 Months

-37.1%

How does BEAM drawdown profile look like?

BEAM Financial Health

Current Ratio

5.99

BEAM Investor Care

Shares Dilution (1Y)

8.00%

Diluted EPS (TTM)

-1.6

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	76.7M	80.2M	81.6M	377.7M
2022	54.1M	56.4M	58.7M	60.9M
2021	13.0M	25.9M	38.9M	51.8M
2020	0	0	0	24.0K
2019	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Beam Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 26, 2024	burrell terry-ann	acquired	-	-	12,500	chief financial officer
Apr 02, 2024	simon amy	sold	-504,851	30.5415	-16,530	chief medical officer
Apr 01, 2024	evans john m.	sold	-581,617	32.13	-18,102	ceo
Apr 01, 2024	burrell terry-ann	sold	-174,926	32.12	-5,446	chief financial officer
Apr 01, 2024	bellon christine	sold	-109,240	32.12	-3,401	chief legal officer
Apr 01, 2024	ciaramella giuseppe	sold	-145,632	32.12	-4,534	president
Apr 01, 2024	simon amy	sold	-229,954	32.13	-7,157	chief medical officer
Mar 31, 2024	burrell terry-ann	acquired	-	-	27,500	chief financial officer
Mar 31, 2024	bellon christine	acquired	-	-	27,500	chief legal officer
Mar 31, 2024	simon amy	acquired	-	-	27,500	chief medical officer

Which funds bought or sold BEAM recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 08, 2024	STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM	added	0.05	68,000	609,950	-%
May 08, 2024	Sandy Spring Bank	new	-	39,648	39,648	-%
May 08, 2024	TD Asset Management Inc	new	-	5,375,340	5,375,340	-%
May 08, 2024	Russell Investments Group, Ltd.	added	4.43	1,003,190	4,752,100	0.01%
May 08, 2024	US BANCORP \DE\	added	11.25	19,239	74,141	-%
May 08, 2024	PROFUND ADVISORS LLC	reduced	-30.22	-230,530	1,276,530	0.05%
May 08, 2024	ProShare Advisors LLC	added	10.62	164,536	644,643	-%
May 08, 2024	KBC Group NV	unchanged	-	10,000	59,000	-%
May 08, 2024	Bell Investment Advisors, Inc	unchanged	-	133	760	-%
May 07, 2024	Arizona State Retirement System	added	1.17	116,796	629,049	-%

Are Funds Buying or Selling BEAM?

Are funds buying BEAM calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BEAM

No. of Funds

Unveiling Beam Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	arch venture fund ix, l.p.	6.7%	5,443,039	SC 13G/A
Feb 13, 2024	vanguard group inc	8.79%	7,164,843	SC 13G/A
Feb 12, 2024	farallon capital partners, l.p.	0.7%	542,347	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 06, 2024	temasek holdings (private) ltd	3.8%	3,076,117	SC 13G/A
Jan 29, 2024	ark investment management llc	11.53%	9,393,889	SC 13G/A
Jan 25, 2024	blackrock inc.	8.2%	6,662,043	SC 13G/A
Jan 24, 2024	state street corp	5.66%	4,616,358	SC 13G
Sep 22, 2023	farallon capital partners, l.p.	0.4%	306,547	SC 13G
Mar 17, 2023	temasek holdings (private) ltd	5.0%	3,644,573	SC 13G

Recent SEC filings of Beam Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 07, 2024	10-Q	Quarterly Report
May 07, 2024	8-K	Current Report
Apr 29, 2024	4	Insider Trading
Apr 19, 2024	ARS	ARS
Apr 19, 2024	DEF 14A	DEF 14A
Apr 19, 2024	DEFA14A	DEFA14A
Apr 04, 2024	144	Notice of Insider Sale Intent
Apr 04, 2024	144	Notice of Insider Sale Intent
Apr 04, 2024	144	Notice of Insider Sale Intent
Apr 04, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Beam Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	47.0B	6.8B	9.93%	-6.23%	-7.88	6.87	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.2B	2.0B	-2.86%	-28.22%	-57.69	9.56	75.20%	68.82%
BMRN	15.5B	2.5B	-8.14%	-14.08%	75.54	6.28	13.74%	186.89%
INCY	12.0B	3.8B	-3.24%	-16.29%	16.12	3.19	8.58%	129.81%
MID-CAP
BBIO	5.4B	107.9M	1.09%	107.81%	-9.83	48.09	54.84%	-28.31%
APLS	5.2B	524.1M	-22.77%	-53.41%	-12.37	9.85	394.93%	39.61%
AXSM	3.5B	251.0M	1.40%	-8.18%	-11.81	13.94	73.58%	-86.73%
ARWR	3.1B	240.7M	-5.68%	-38.85%	-6.52	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-16.31%	-29.84%	-1.5K	3.09	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	-0.76%	-10.51%	28.42	4.5	60.38%	-34.49%
NVAX	627.0M	983.7M	1.36%	-50.17%	-1.15	0.64	-50.36%	17.16%
CRBP	467.5M	881.7K	16.76%	369.92%	-13.85	481.06	-77.61%	33.36%
INO	260.8M	4.9M	-4.04%	14.81%	-1.93	53.59	-54.97%	51.71%
IBIO	6.4M	2.1M	-14.75%	74.53%	-0.24	2.14	-13.45%	66.37%

Beam Therapeutics Inc News

Latest updates

Beam Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-100.0%	-	316,192,000	17,193,000	20,116,000	24,208,000	20,037,000	15,799,000	16,652,000	8,432,000	6,325,500	4,219,000	2,112,500	6,000	6,000	6,000	162,800	319,600	476,400	633,200	790,000	498,000
Operating Expenses	-39.2%	111,542,000	183,334,000	125,460,000	122,264,000	123,136,000	109,022,000	107,102,000	98,618,000	84,657,000	114,553,000	70,397,000	58,980,000	200,379,000	40,805,000	37,327,000	26,291,000	28,361,000	26,377,000	18,030,000	17,657,000	13,108,000
S&GA Expenses	-100.0%	-	43,257,000	25,410,000	24,656,000	23,490,000	22,681,000	21,815,000	24,062,000	19,247,000	17,772,000	15,774,000	13,403,000	10,273,000	8,354,000	7,502,000	6,937,000	6,812,000	6,160,000	5,487,000	4,977,000	3,929,000
R&D Expenses	-39.4%	84,818,000	140,077,000	100,050,000	97,608,000	99,646,000	86,341,000	85,287,000	74,556,000	65,410,000	96,781,000	54,623,000	45,577,000	190,106,000	32,451,000	29,825,000	19,354,000	21,549,000	20,217,000	12,543,000	12,680,000	9,179,000
EBITDA Margin	1.5%	-0.13	-0.13	-2.96	-3.03	-3.19	-4.03	-6.09	-6.37	-6.67	-6.99	-4.83	-7.27	-	-	-	-	-	-	-	-	-
Interest Expenses	-30.0%	14,000	20,000	28,000	50,000	62,000	76,000	86,000	101,000	113,000	124,000	136,000	148,000	159,000	139,000	140,000	-	-	-	-	-	-
Income Taxes	-100.0%	-	1,366,000	-	-	-	1,000,000	2,400,000	-	-	-	-	-	159,000	-422,000	140,000	148,000	134,000	-	-	-	-
Earnings Before Taxes	-100.0%	-	144,163,000	-96,088,000	-	-	-37,349,000	-81,665,000	-	-	-	-28,118,000	-	-	-	-	-	-	-	-	-	-
EBT Margin	0%	-0.19	-0.19	-3.19	-3.25	-3.39	-4.27	-6.32	-6.57	-6.85	-7.15	-5.00	-7.50	-	-	-	-	-	-	-	-	-
Net Income	-169.1%	-98,669,000	142,797,000	-96,088,000	-82,776,000	-96,460,000	-38,349,000	-109,575,000	-71,950,000	-69,214,000	-64,707,000	-28,118,000	-76,253,000	-201,560,000	-95,464,000	-34,452,000	-34,218,000	-30,458,000	-27,850,000	-19,005,000	-17,861,000	-13,610,000
Net Income Margin	-1.7%	-0.36	-0.35	-3.85	-4.08	-4.12	-4.75	-5.38	-4.15	-4.40	-7.15	-10.32	-15.72	-	-	-	-	-	-	-	-	-
Free Cashflow	-177.7%	-102,185,000	131,484,000	-97,732,000	-100,847,000	-115,832,000	-77,452,000	-86,283,000	-73,920,000	211,231,000	-11,539,000	-2,773,000	-48,711,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																		(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Assets	-6.8%	1,360	1,460	1,291	1,354	1,332	1,342	1,350	1,418	1,453	1,474	1,157	893	693	452	278	300	323	156
Current Assets	-7.4%	1,122	1,211	1,040	1,095	1,083	1,093	1,109	1,180	1,239	1,273	941	678	515	308	209	235	260	95.00
Cash Equivalents	-32.5%	294	436	169	226	250	233	157	266	297	560	612	212	97.00	177	138	125	126	51.00
Net PPE	-3.2%	121	125	128	128	122	116	111	106	94.00	84.00	72.00	64.00	52.00	39.00	29.00	26.00	25.00	24.00
Liabilities	-6.7%	446	478	512	542	571	608	636	618	624	648	303	345	271	206	78.00	69.00	61.00	55.00
Current Liabilities	-8.9%	187	206	220	210	220	224	239	212	219	213	101	129	102	102	47.00	39.00	31.00	29.00
Shareholder's Equity	-6.9%	913	981	779	812	762	733	714	800	829	827	854	549	422	246	200	231	261	-
Retained Earnings	-8.3%	-1,288	-1,189	-1,332	-1,200	-1,153	-1,057	-1,019	-909	-837	-768	-703	-675	-599	-397	-302	-267	-233	-203
Additional Paid-In Capital	1.5%	2,202	2,170	2,113	2,049	1,915	1,793	1,737	1,713	1,669	1,594	1,557	1,223	1,021	643	502	498	495	2.00
Shares Outstanding	0.8%	82.00	82.00	79.00	78.00	74.00	71.00	70.00	70.00	69.00	64.00	63.00	62.00	-	-	-	-	-	-
Float	-	-	-	-	2,110	-	-	-	2,460	-	-	-	6,450	-	-	-	982	-	-

Cashflow (Last 12 Months)

(In Millions)

Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-173.8%	-99.75	135	-89.78	-84.67	-109	-69.19	-74.50	-52.28	218	2.00	3.00	-32.53	-38.58	-24.30	-21.21	-22.84	-27.39	-17.80	-16.99	-11.35	-25.86
Share Based Compensation	29.5%	29.00	23.00	26.00	26.00	24.00	22.00	22.00	22.00	18.00	16.00	13.00	10.00	5.00	7.00	3.00	3.00	3.00	2.00	2.00	2.00	1.00
Cashflow From Investing	-154.5%	-53.46	98.00	-10.23	-41.48	25.00	113	-36.17	-1.26	-537	-77.50	76.00	-13.14	-279	-81.43	35.00	23.00	-76.79	17.00	14.00	-95.08	-2.35
Cashflow From Financing	-91.4%	3.00	34.00	37.00	108	98.00	32.00	2.00	22.00	56.00	22.00	321	160	253	130	0.00	-0.78	193	1.00	3.00	-0.02	38.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

BEAM Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
License and collaboration revenue	$ 7,410	$ 24,208
Revenue, Product and Service [Extensible List]	us-gaap:LicenseMember	us-gaap:LicenseMember
Operating expenses:
Research and development	$ 84,818	$ 99,646
General and administrative	26,724	23,490
Total operating expenses	111,542	123,136
Loss from operations	(104,132)	(98,928)
Other income (expense):
Change in fair value of derivative liabilities	(2,900)	5,600
Change in fair value of non-controlling equity investments	(3,353)	(12,797)
Change in fair value of contingent consideration liabilities	(133)	(296)
Interest and other income (expense), net	11,849	9,961
Total other income (expense)	5,463	2,468
Net loss	(98,669)	(96,460)
Unrealized gain (loss) on marketable securities	(1,525)	1,665
Comprehensive loss	$ (100,194)	$ (94,795)
Net loss per common share, basic	$ (1.21)	$ (1.33)
Net loss per common share, diluted	$ (1.21)	$ (1.33)
Weighted - average common shares outstanding, basic	81,698,633	72,273,829
Weighted - average common shares outstanding, diluted	81,698,633	72,273,829

BEAM Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 287,848	$ 435,895
Marketable securities	806,706	753,981
Prepaid expenses and other current assets	27,156	21,167
Total current assets	1,121,710	1,211,043
Property and equipment, net	120,922	124,960
Restricted cash	6,452	8,719
Operating lease right-of-use assets	109,023	112,846
Other assets	1,689	2,146
Total assets	1,359,796	1,459,714
Current liabilities:
Accounts payable	2,790	1,617
Accrued expenses and other current liabilities	86,437	111,664
Derivative liabilities	13,700	10,800
Current portion of deferred revenue	72,111	68,706
Current portion of lease liability	12,181	12,778
Total current liabilities	187,219	205,565
Long-term lease liability	155,939	159,911
Contingent consideration liabilities	2,856	2,723
Long-term portion of deferred revenue	99,573	109,888
Other liabilities	719	298
Total liabilities	446,306	478,385
Commitments and contingencies (See Note 7, License agreements and Note 8, Collaboration and license agreements)
Stockholders’ equity:
Preferred stock, $0.01 par value; 25,000,000 shares authorized, and no shares issued or outstanding at March 31, 2024 and December 31, 2023, respectively
Common stock, $0.01 par value; 250,000,000 shares authorized, 82,280,827 and 81,632,496 issued and outstanding at March 31, 2024 and December 31, 2024, respectively	823	816
Additional paid-in capital	2,202,146	2,169,798
Accumulated other comprehensive (loss) income	(921)	604
Accumulated deficit	(1,288,558)	(1,189,889)
Total stockholders' equity	913,490	981,329
Total liabilities and stockholders' equity	$ 1,359,796	$ 1,459,714

About Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 and BEAM-102 for the treatment of sickle cell disease beta thalassemia; BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease; and the Institute of Molecular and Clinical Ophthalmology Basel for treatment of impaired vision and blindness. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

CEO	Mr. John M. Evans M.B.A.
WEBSITE	https://beamtx.com
INDUSTRY	Biotechnology
EMPLOYEES	532

Beam Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Beam Therapeutics Inc? What does BEAM stand for in stocks?

BEAM is the stock ticker symbol of Beam Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Beam Therapeutics Inc (BEAM)?

As of Thu May 09 2024, market cap of Beam Therapeutics Inc is 1.86 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BEAM stock?

You can check BEAM's fair value in chart for subscribers.

What is the fair value of BEAM stock?

You can check BEAM's fair value in chart for subscribers. The fair value of Beam Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Beam Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BEAM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Beam Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether BEAM is over valued or under valued. Whether Beam Therapeutics Inc is cheap or expensive depends on the assumptions which impact Beam Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BEAM.

What is Beam Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 09 2024, BEAM's PE ratio (Price to Earnings) is -13.77 and Price to Sales (PS) ratio is 4.91. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BEAM PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Beam Therapeutics Inc's stock?

In the past 10 years, Beam Therapeutics Inc has provided -0.127 (multiply by 100 for percentage) rate of return.